LakeShore Biopharma Co., Ltd
LSB · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $614,962 | $573,418 | $687,201 | $502,950 |
| % Growth | 7.2% | -16.6% | 36.6% | – |
| Cost of Goods Sold | $107,772 | $117,688 | $153,360 | $121,460 |
| Gross Profit | $507,189 | $455,730 | $533,841 | $381,490 |
| % Margin | 82.5% | 79.5% | 77.7% | 75.9% |
| R&D Expenses | $146,369 | $302,801 | $318,701 | $211,222 |
| G&A Expenses | $135,992 | $147,648 | $81,764 | $107,049 |
| SG&A Expenses | $390,735 | $428,093 | $333,321 | $272,766 |
| Sales & Mktg Exp. | $254,743 | $280,445 | $251,558 | $165,716 |
| Other Operating Expenses | $56,377 | $170,668 | $21,201 | $16,461 |
| Operating Expenses | $593,481 | $901,562 | $673,223 | $500,449 |
| Operating Income | -$86,292 | -$445,833 | -$139,382 | -$118,959 |
| % Margin | -14% | -77.7% | -20.3% | -23.7% |
| Other Income/Exp. Net | -$14,637 | -$9,361 | -$142,955 | -$112,771 |
| Pre-Tax Income | -$100,929 | -$455,193 | -$282,337 | -$231,730 |
| Tax Expense | -$947 | -$21,729 | $1,134 | $4,937 |
| Net Income | -$99,982 | -$433,465 | -$145,479 | -$236,667 |
| % Margin | -16.3% | -75.6% | -21.2% | -47.1% |
| EPS | -0.94 | -4.05 | -1.88 | -0.019 |
| % Growth | 76.8% | -115.4% | -10,062.2% | – |
| EPS Diluted | -0.94 | -4.05 | -1.88 | -0.019 |
| Weighted Avg Shares Out | 106,923 | 106,923 | 77,422 | 29,500 |
| Weighted Avg Shares Out Dil | 106,923 | 106,923 | 77,422 | 29,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $15,739 | $44,345 | $30,858 | $2,717 |
| Depreciation & Amortization | $36,652 | $42,185 | $36,688 | $31,154 |
| EBITDA | -$48,538 | -$368,663 | -$76,800 | -$67,196 |
| % Margin | -7.9% | -64.3% | -11.2% | -13.4% |